366 related articles for article (PubMed ID: 22960403)
1. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Leinung MC; Grasso P
Regul Pept; 2012 Nov; 179(1-3):33-8. PubMed ID: 22960403
[TBL] [Abstract][Full Text] [Related]
2. [D-Leu-4]-OB3, an orally bioavailable leptin-related synthetic peptide insulin sensitizer: a study comparing the efficacies of [D-Leu-4]-OB3 and metformin on energy balance and glycemic regulation in insulin-deficient male Swiss Webster mice.
Novakovic ZM; Leinung MC; Grasso P
Peptides; 2013 May; 43():167-73. PubMed ID: 23500518
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin-resistant C57BLK/6-m db/db mice.
Waldrop MA; Leinung MC; Lee DW; Grasso P
Diabetes Obes Metab; 2010 Oct; 12(10):871-5. PubMed ID: 20920039
[TBL] [Abstract][Full Text] [Related]
4. Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacy.
Novakovic ZM; Anderson BM; Grasso P
Peptides; 2014 Dec; 62():176-82. PubMed ID: 25453979
[TBL] [Abstract][Full Text] [Related]
5. [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, small molecule synthetic peptide leptin mimetics, improve glycemic control in diet-induced obese (DIO) mice.
Wang A; Anderson BM; Novakovic ZM; Grasso P
Peptides; 2018 Mar; 101():51-59. PubMed ID: 29269073
[TBL] [Abstract][Full Text] [Related]
6. [D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice.
Grasso P; Rozhavskaya-Arena M; Leinung MC; Lee DW
Regul Pept; 2001 Sep; 101(1-3):123-9. PubMed ID: 11495687
[TBL] [Abstract][Full Text] [Related]
7. Design of a synthetic leptin agonist: effects on energy balance, glucose homeostasis, and thermoregulation.
Rozhavskaya-Arena M; Lee DW; Leinung MC; Grasso P
Endocrinology; 2000 Jul; 141(7):2501-7. PubMed ID: 10875251
[TBL] [Abstract][Full Text] [Related]
8. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice.
Lee DW; Leinung MC; Grasso P
Regul Pept; 2008 Oct; 150(1-3):62-5. PubMed ID: 18455249
[TBL] [Abstract][Full Text] [Related]
9. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration.
Lee DW; Leinung MC; Grasso P
Regul Pept; 2010 Feb; 160(1-3):129-32. PubMed ID: 20026361
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels.
Novakovic ZM; Leinung MC; Lee DW; Grasso P
Diabetes Obes Metab; 2010 Jun; 12(6):532-9. PubMed ID: 20518808
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems.
Novakovic ZM; Leinung MC; Lee DW; Grasso P
Regul Pept; 2009 Apr; 154(1-3):107-11. PubMed ID: 19344673
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
14. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
[TBL] [Abstract][Full Text] [Related]
15. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
[TBL] [Abstract][Full Text] [Related]
16. Oral delivery of [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, synthetic peptide leptin mimetics: Immunofluorescent localization in the mouse hypothalamus.
Anderson BM; Jacobson L; Novakovic ZM; Grasso P
Brain Res; 2017 Jun; 1664():1-8. PubMed ID: 28347670
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Safety of MA-[D-Leu-4]-OB3, a Synthetic Peptide Leptin Mimetic: Two Pre-Clinical Toxicity Studies in Male and Female C57BL/6 Mice.
Enemark F; Novakovic ZM; Grasso P
Int J Toxicol; 2023 Dec; 42(6):504-514. PubMed ID: 37556196
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Sheffield CA; Kane MP; Busch RS
Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
20. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
